Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.

Welie AG, Gebretekle GB, Stolk E, Mukuria C, Krahn MD, Enquoselassie F, Fenta TG.

Value Health Reg Issues. 2019 Nov 1;22:7-14. doi: 10.1016/j.vhri.2019.08.475. [Epub ahead of print]

PMID:
31683254
2.

Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada.

Bremner KE, Yabroff KR, Coughlan D, Liu N, Zeruto C, Warren JL, de Oliveira C, Mariotto AB, Lam C, Barrett MJ, Chan KK, Hoch JS, Krahn MD.

J Oncol Pract. 2019 Oct 24:JOP1900061. doi: 10.1200/JOP.19.00061. [Epub ahead of print]

PMID:
31647697
3.

Home Dialysis Is Associated with Lower Costs and Better Survival than Other Modalities: A Population-Based Study in Ontario, Canada.

Krahn MD, Bremner KE, de Oliveira C, Dixon SN, McFarlane P, Garg AX, Mitsakakis N, Blake PG, Harvey R, Pechlivanoglou P.

Perit Dial Int. 2019 Nov-Dec;39(6):553-561. doi: 10.3747/pdi.2018.00268. Epub 2019 Oct 3.

PMID:
31582466
4.

The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach.

Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD.

Liver Int. 2019 Sep 11. doi: 10.1111/liv.14247. [Epub ahead of print]

PMID:
31509639
5.

Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.

Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD.

Syst Rev. 2019 Aug 19;8(1):207. doi: 10.1186/s13643-019-1126-1.

6.

Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease.

Nam A, Naimark DMJ, Stanbrook MB, Krahn MD.

MDM Policy Pract. 2019 May 27;4(1):2381468319852358. doi: 10.1177/2381468319852358. eCollection 2019 Jan-Jun.

7.

Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.

Erman A, Masucci L, Krahn MD, Elterman DS.

BJU Int. 2018 Nov;122(5):879-888. doi: 10.1111/bju.14520. Epub 2018 Sep 11.

8.

Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions.

Nathan PC, Bremner KE, Liu N, Gupta S, Greenberg ML, McBride ML, Krahn MD, de Oliveira C.

J Natl Cancer Inst. 2019 Mar 1;111(3):322-330. doi: 10.1093/jnci/djy119.

9.

Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia.

Masucci L, Erman A, Krahn MD, Elterman D.

Can Urol Assoc J. 2018 Jun 19. doi: 10.5489/cuaj.5267. [Epub ahead of print]

10.

The lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payer.

Chan BC, Cadarette SM, Wodchis WP, Krahn MD, Mittmann N.

J Spinal Cord Med. 2019 Mar;42(2):184-193. doi: 10.1080/10790268.2018.1486622. Epub 2018 Jun 20.

PMID:
29923798
11.

The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer.

Perlis N, Krahn MD, Boehme KE, Alibhai SMH, Jamal M, Finelli A, Sridhar SS, Chung P, Gandhi R, Jones J, Tomlinson G, Bremner KE, Kulkarni G.

J Urol. 2018 Aug;200(2):283-291. doi: 10.1016/j.juro.2018.03.006. Epub 2018 Mar 9.

PMID:
29530786
12.

The economic burden of cancer care in Canada: a population-based cost study.

de Oliveira C, Weir S, Rangrej J, Krahn MD, Mittmann N, Hoch JS, Chan KKW, Peacock S.

CMAJ Open. 2018 Jan 4;6(1):E1-E10. doi: 10.9778/cmajo.20170144. Epub 2018 Jan 4.

13.

Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis.

Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, Wong WWL, Grootendorst P, Krahn MD.

J Viral Hepat. 2018 May;25(5):502-513. doi: 10.1111/jvh.12846. Epub 2018 Jan 24. Review.

PMID:
29239068
14.

Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.

Mühlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Sroczynski G, Siebert U.

BMC Public Health. 2017 Jun 26;17(1):596. doi: 10.1186/s12889-017-4439-9.

15.

Costs of cancer care in children and adolescents in Ontario, Canada.

de Oliveira C, Bremner KE, Liu N, Greenberg ML, Nathan PC, McBride ML, Krahn MD.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26628. Epub 2017 May 13.

PMID:
28500732
16.

Costs for Childhood and Adolescent Cancer, 90 Days Prediagnosis and 1 Year Postdiagnosis: A Population-Based Study in Ontario, Canada.

de Oliveira C, Bremner KE, Liu N, Greenberg ML, Nathan PC, McBride ML, Krahn MD.

Value Health. 2017 Mar;20(3):345-356. doi: 10.1016/j.jval.2016.10.010. Epub 2016 Dec 1.

17.

Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison.

De Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, Hoch JS, Peacock S, Krahn MD.

Healthc Policy. 2017 Feb;12(3):95-108.

18.

Long-term health care costs for prostate cancer patients on androgen deprivation therapy.

Krahn MD, Bremner KE, Luo J, Tomlinson G, Alibhai SM.

Curr Oncol. 2016 Oct;23(5):e443-e453. Epub 2016 Oct 25.

19.

Phase-specific and lifetime costs of cancer care in Ontario, Canada.

de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, Hoch JS, Peacock S, Krahn MD.

BMC Cancer. 2016 Oct 18;16(1):809.

20.

Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.

Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S, Tomlinson GA.

Cancer. 2017 Jan 1;123(2):237-244. doi: 10.1002/cncr.30320. Epub 2016 Sep 1.

21.

Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.

Gong IY, Verma S, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Brezden-Masley CB, Gavura S, Peacock S, Chan KK.

Breast Cancer Res Treat. 2016 Jun;157(3):535-44. doi: 10.1007/s10549-016-3823-y. Epub 2016 Jun 6.

PMID:
27271767
22.

Disparities in a provision of in-hospital post-arrest interventions for out-of-hospital cardiac arrest (OHCA) in the elderly population-protocol for a systematic review.

Bielecki JM, Wong J, Mitsakakis N, Shah PS, Krahn MD, Rac VE.

Syst Rev. 2016 Apr 7;5:55. doi: 10.1186/s13643-016-0234-4.

23.

Population-based trends in systemic therapy use and cost for cancer patients in the last year of life.

Pataky RE, Cheung WY, de Oliveira C, Bremner KE, Chan KK, Hoch JS, Krahn MD, Peacock SJ.

Curr Oncol. 2016 Feb;23(Suppl 1):S32-41. doi: 10.3747/co.23.2946. Epub 2016 Feb 29.

24.

A multi-level qualitative analysis of Telehomecare in Ontario: challenges and opportunities.

Hunting G, Shahid N, Sahakyan Y, Fan I, Moneypenny CR, Stanimirovic A, North T, Petrosyan Y, Krahn MD, Rac VE.

BMC Health Serv Res. 2015 Dec 9;15:544. doi: 10.1186/s12913-015-1196-2.

25.

Performance of the disease risk score in a cohort study with policy-induced selection bias.

Tadrous M, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM.

J Comp Eff Res. 2015 Nov;4(6):607-14. doi: 10.2217/cer.15.40. Epub 2015 Nov 3.

PMID:
26529307
26.

Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.

Jahn B, Rochau U, Kurzthaler C, Paulden M, Kluibenschädl M, Arvandi M, Kühne F, Goehler A, Krahn MD, Siebert U.

Med Decis Making. 2016 Apr;36(3):375-90. doi: 10.1177/0272989X15604158. Epub 2015 Oct 16.

PMID:
26476865
27.

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.

Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK.

J Natl Cancer Inst. 2015 Oct 16;108(1). pii: djv301. doi: 10.1093/jnci/djv301. Print 2016 Jan.

PMID:
26476433
28.

An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data.

Bremner KE, Krahn MD, Warren JL, Hoch JS, Barrett MJ, Liu N, Barbera L, Yabroff KR.

Palliat Med. 2015 Dec;29(10):918-28. doi: 10.1177/0269216315596505. Epub 2015 Sep 1.

PMID:
26330452
29.

The ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening.

Mühlberger N, Kurzthaler C, Iskandar R, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U.

Med Decis Making. 2015 Aug;35(6):758-72. doi: 10.1177/0272989X15585114. Epub 2015 May 14.

PMID:
25977360
30.

Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.

Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, Chan KK.

Breast Cancer Res Treat. 2015 Jun;151(3):639-52. doi: 10.1007/s10549-015-3382-7. Epub 2015 May 12.

PMID:
25962692
31.

The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening.

Mühlberger N, Heijnsdijk EA, Kurzthaler C, Iskandar R, Krahn MD, Bremner K, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U.

Value Health. 2014 Nov;17(7):A559. doi: 10.1016/j.jval.2014.08.1843. Epub 2014 Oct 26. No abstract available.

32.

Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study.

de Oliveira C, Bremner KE, Pataky R, Gunraj N, Haq M, Chan K, Cheung WY, Hoch JS, Peacock S, Krahn MD.

CMAJ Open. 2013 Dec 9;1(4):E151-8. doi: 10.9778/cmajo.20130041. eCollection 2013 Oct.

33.

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis-reply to Pazianas and Abrahamsen.

Tadrous M, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM.

Osteoporos Int. 2014 Nov;25(11):2671-2. doi: 10.1007/s00198-014-2789-z. Epub 2014 Jul 18. No abstract available.

PMID:
25035138
34.

Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Krahn MD, Bremner KE, Luo J, Alibhai SM.

Curr Oncol. 2014 Jun;21(3):e457-65. doi: 10.3747/co.21.1865.

35.

Systematic review, critical appraisal, and analysis of the quality of economic evaluations in stroke imaging.

Burton KR, Perlis N, Aviv RI, Moody AR, Kapral MK, Krahn MD, Laupacis A.

Stroke. 2014 Mar;45(3):807-14. doi: 10.1161/STROKEAHA.113.004027. Epub 2014 Feb 11. Review.

PMID:
24519409
36.

Response to "the life table method of half-cycle correction: getting it right".

Naimark DM, Kabboul NN, Krahn MD.

Med Decis Making. 2014 Apr;34(3):286-7. doi: 10.1177/0272989X14520719. Epub 2014 Jan 22. No abstract available.

PMID:
24452200
37.

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.

Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM.

Osteoporos Int. 2014 Apr;25(4):1225-35. doi: 10.1007/s00198-013-2576-2. Epub 2013 Nov 28.

PMID:
24287510
38.

Use of forecasted assessment of quality of life to validate time-trade-off utilities and a prostate cancer screening decision-analytic model.

Cantor SB, Deshmukh AA, Krahn MD, Volk RJ.

Health Expect. 2015 Oct;18(5):1610-20. doi: 10.1111/hex.12150. Epub 2013 Oct 23.

39.

Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS).

Bremner KE, Mitsakakis N, Wilson L, Krahn MD.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):47-56. doi: 10.1038/pcan.2013.44. Epub 2013 Oct 15. Erratum in: Prostate Cancer Prostatic Dis. 2014 Mar;17(1):98-104.

PMID:
24126796
40.

The half-cycle correction revisited: redemption of a kludge.

Naimark DM, Kabboul NN, Krahn MD.

Med Decis Making. 2013 Oct;33(7):961-70. doi: 10.1177/0272989X13501558.

PMID:
24048350
41.

Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada.

de Oliveira C, Bremner KE, Ni A, Alibhai SM, Laporte A, Krahn MD.

J Cancer Surviv. 2014 Mar;8(1):9-20. doi: 10.1007/s11764-013-0305-7. Epub 2013 Aug 23.

PMID:
23975612
42.

Health care costs for state transition models in prostate cancer.

Krahn MD, Bremner KE, Zagorski B, Alibhai SM, Chen W, Tomlinson G, Mitsakakis N, Naglie G.

Med Decis Making. 2014 Apr;34(3):366-78. doi: 10.1177/0272989X13493970. Epub 2013 Jul 26.

PMID:
23894082
43.

Medical therapy v. PCI in stable coronary artery disease: a cost-effectiveness analysis.

Wijeysundera HC, Tomlinson G, Ko DT, Dzavik V, Krahn MD.

Med Decis Making. 2013 Oct;33(7):891-905. doi: 10.1177/0272989X13497262. Epub 2013 Jul 25.

PMID:
23886676
44.

Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis.

de Oliveira C, Nguyen HV, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, Liu PP, Krahn MD.

CMAJ Open. 2013 Jul 25;1(2):E83-90. doi: 10.9778/cmajo.20130003. eCollection 2013 May.

45.

A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.

Krahn MD, Bremner KE, Alibhai SM, Ni A, Tomlinson G, Laporte A, Naglie G.

Qual Life Res. 2013 Dec;22(10):2951-62. doi: 10.1007/s11136-013-0401-1. Epub 2013 Apr 6.

PMID:
23564620
46.

Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.

Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM.

Osteoporos Int. 2013 Oct;24(10):2571-9. doi: 10.1007/s00198-013-2343-4. Epub 2013 Apr 6.

PMID:
23563932
47.

Health care costs associated with hepatocellular carcinoma: a population-based study.

Thein HH, Isaranuwatchai W, Campitelli MA, Feld JJ, Yoshida E, Sherman M, Hoch JS, Peacock S, Krahn MD, Earle CC.

Hepatology. 2013 Oct;58(4):1375-84. doi: 10.1002/hep.26231. Epub 2013 Mar 15.

PMID:
23300063
48.

Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study.

de Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S, Krahn MD.

CMAJ Open. 2013 Jan 16;1(1):E1-8. doi: 10.9778/cmajo.20120013. eCollection 2013 Jan.

49.

Canada's contribution to global research in cardiovascular diseases.

Nguyen HV, de Oliveira C, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, Liu PP, Krahn MD.

Can J Cardiol. 2013 Jun;29(6):742-6. doi: 10.1016/j.cjca.2012.09.013. Epub 2012 Dec 6. Review.

PMID:
23219608
50.

Economic analysis of Heart and Stroke Foundation of Ontario's Hypertension Management Initiative.

de Oliveira C, Wijeysundera HC, Tobe SW, Lum-Kwong MM, Von Sychowski S, Wang X, Tu JV, Krahn MD.

Clinicoecon Outcomes Res. 2012;4:323-36. doi: 10.2147/CEOR.S33390. Epub 2012 Nov 13.

Supplemental Content

Loading ...
Support Center